ENSG vs SLN
Ensign Group vs Silence Therapeutics plc — AI-powered side-by-side comparison
VS
SLN
Silence Therapeutics plc
48
Watch
| Metric | ENSG | SLN |
|---|
| AI Score |
69
|
48
|
| Price |
$180.10
|
$14.69
|
| P/E Ratio |
27.43×
|
-6.72×
|
| ROE |
15.4%
|
-142.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
14.1%
|
68.6%
|
| Debt / Equity |
0.92×
|
0.00×
|
| Dividend Yield |
0.1%
|
0.0%
|
| RSI (14) |
71.8
|
74.4
|
| Beta |
0.694
|
1.351
|
| Expected Upside |
+5.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ENSG versus SLN.
ENSG leads by 21 points.
ENSG scores 69/100 (Buy) versus SLN at 48/100 (Watch).
ENSG Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- RSI at 72 is in overbought territory — Technical
SLN Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -99.3% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -103.3% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.02 adds balance-sheet risk to the value case — Value
- Revenue declining -99.3% YoY -- this is not a growth story right now — Growth